

VI. DAFTAR PUSTAKA

- Achanta, G., Modzelewska, A., Feng, L., Khan, S.R., Huang, P.A., A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome, *Mol. Pharmacol.*, 70(1):426-433. <https://doi.org/10.1124/mol.105.021311>
- Agu, P. C., Afiukwa, C.A., Orji, O.U., Ezech, E.M., Ofoke, I.H., Ogbu, C.O., Ugwuja, E.I., Aja, P.M., 2023, Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management, *Sci.Rep.*, 13(1), 1-12. <https://doi.org/10.1038/s41598-023-40160-2>
- Anjudikkal J., Shukla A., Pulikkal A., K. 2025. Effect of spacer of cationic gemini surfactant on solubility and stability of curcumin. *Mol. Liq.*, 426(127345): 1-11. <https://doi.org/10.1016/j.molliq.2025.127345>
- Almeida, C.F., Correia, G., Teixeira, N., Amaral, C., 2024, Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies, *Bio. Pharm.*, 223, 1-18. <https://doi.org/10.1016/j.bcp.2024.116178>
- Bagaria, S.P., Ray, P.S., Sim, M., Ye, X., Shamonki, J.M., Cui, X., Giuliano, A.E., 2014, Personalizing breast cancer staging by the inclusion of ER, PR, and HER2, *JAMA. Sur.*, 149(2), 125-129. 10.1001/jamasurg.2013.3181
- Bandyopadhyay, A., Gao, J., 2015, Targeting biomolecules with reversible covalent chemistry, *Curr. Opin. Chem. Biol.*, 34, 110-116. doi:10.1016/j.cbpa.2016.08.011.
- Barmatz, V., S., Arif, T., Kuzmine, A., S. 2023. Apoptotic proteins with non-apoptotic activity: expression and function in cancer. *Apoptosis*, 28: 730-753. <https://doi.org/10.1007/s10495-023-01835-3>
- Belina, E., Umar, M., Theodorus., 2025. Chemotherapy and quality of life in breast cancer patients: a case-series study in Palembang, Indonesia. *Sriwijaya J. Sur.*, 8(1), 814-825. <http://dx.doi.org/10.37275/sjs.v8i1.120>.
- Cailleau, R., Young, R., Olive, M., Reeves, W.J., 1974, Breast tumor cell lines from pleural effusions, *J. Nat. Can. Ins.*, 53(3): 661-674. doi:10.1093/jnci/53.3.661
- Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., Alimonti, A., 2019, Cellular senescence: aging, cancer, and injury, *Phy. Rev.*, 99(2), 1047-1078.
- Cen, P., Cui, C., Huang, J., Chen, H., Wu, F., Niu, J., Zhong, Y., Jin, C., Zhu, W., Zhang, H., Tian, M., 2024, Cellular senescence imaging and senolysis monitoring in cancer therapy based on a β -galactosidase-activated aggregation-induced emission luminogen, *Acta. Biomat.*, 340-353. <https://doi.org/10.1016/j.actbio.2024.03.027>
- Charan, M., Das, S., Mishra, S., Chatterjee, N., Varikuti, S., Kaul, K., Misri, S., Ahirwar, D.K., Satorkar, A.R., Ganju, R.K., 2020, Macrophage migration

inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer, *Cell. Death. Dis.*, 11, 774, 1-15.
<https://doi.org/10.1038/s41419-020-02992-y>

- Chen, T., Li, S., Lian, D., Hu, Q., Hou, H., Niu, D., Li, H., Song, L., Gao, Y., Chen, Y., Hu, X., Li, J., Ye, Z., Peng, B., Zhang, G., 2023, Integrated network pharmacology and experimental approach to investigate the protective effect of Jin Gu Lian capsule on rheumatoid arthritis by inhibiting inflammation via IL-17/NF- κ B pathway, *Drug. Des. Dev. Ther.*, 17, 3724-3748.
- Cosar, R., Sut, N., Ozen, A., Tastekin, E., Topaloglu, S., Cicin, I., Nurlu, D., Ozler, T., Demir, S., Yildiz, G., Senodeyici, E., Uzal, M., C., Breast cancer subtypes and prognosis: answers to subgroups classification question, identifying the worst subgroup in our single-center series, *Dove. Med. Press.*, 14, 259-280.
<https://doi.org/10.2147/BCTT.S380754>
- Dai, H., Zhang, S., Zheng, X., Luo, Z., Chen, H., Yao, X., 2023, Advances in β -diketocyclisation of curcumin derivatives and their antitumor activity, 21(2),
<https://doi.org/10.1002/cbdv.202301556>
- Daina A., Zoete, V., 2024, Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning, *Com. Chem.*, 7:105. 1-12.
- Demirgan, R., Karagoz, A., Pekmez, M., Ucar, E., Artun, F.T., Gurer, C., Mat, A., 2016, In vitro anticancer activity and cytotoxicity of some papaver alkaloids on cancer and normal cell lines, *Afr. J. Tradit. Complement. Altern. Med.*, 13(3), 22-26.
- Dreymueller, D., Theodorou, K., Donners, M., Ludwig, A. 2017. Fine tuning cell migration by a disintegrin and metalloproteinases. *Hindawi*, 2017, 9621724, 1-22. <https://doi.org/10.1155/2017/9621724>
- Easmin, S., Pedireddi, V. R., 2023, Supramolecular assemblies in the molecular complexes of 4-cynophenylboronic acid with different N-donor ligands, *RSC Advances*, 13 (33), 23267-23284.
- Ferreira, L.G., Santos, R.N., Oliva, G., Andricopulo, A.D., 2015, Molecular docking and structure-based drug design strategies, *molecules*, 20, 13384-13421. doi:10.3390/molecules200713384
- Fu, M., Peng, Z., Wu, M., Lv, D., Li, Y., Lyu, S., 2024, Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050, *The Breast*, 79, 1-11. <https://doi.org/10.1016/j.breast.2024.103835>
- GBD 2023 Breast Cancer Collaborators, 2026, Global, regional, and national burden of breast cancer among females, 1990-2023, with forecast to 2050: a systematic analysis for the Global Burden of Disease Study 2023, *Lan. On.*, 27. 302-326. [https://doi.org/10.1016/s1470-2045\(25\)00730-2](https://doi.org/10.1016/s1470-2045(25)00730-2)
- Gamrat, J.M., Orme, C.L., Mancini, G.M., Burke, S.J., Althlthol, L.M., Colandrea, R.C., Figula, B.C., Tomares, D.T., Heindl, J.E., Tomsho, J.W., 2025, Boron-

- containing analogs of fosmidomycin: benzoxaborole derivatives exhibit promising activity against resistant pathogens, *ACS Omega*, 10, 31722-31740. <https://doi.org/10.1021/acsomega.5c02701>
- Gfeller, D., Michielin, O., Zoete, V., 2013, Shaping the interaction landscape of bioactive molecules, *Bioinformatics.*, 29:23. 3073-3079.
- Giordano, A., Tommonaro, G., 2019, Curcumin and cancer, *Nutrients*, 11, 2376, 10-20. <https://doi.org/10.3390/nu11102376>
- Girgis, A.S., D'Arcy, P., Aboshouk, D.R., Bekheit, M.S., 2022, Synthesis and bio-properties of 4-piperidone containing compounds as curcumin mimics, *RSC Adv.*, 12, 31102-31123. Doi: 10.1039/d2ra05518j.
- Global Cancer Observatory (GLOBOCAN), "International Agency for Research on Cancer (IARC)", World Health Organization (WHO), Desember 2022. [Daring]. Tersedia pada: <https://gco.iarc.who.int/en>
- Gurunathan, S., Raman, J., Malek, S.N.A., Jhon, P.A., Vikineswary, S., 2013, Green synthesis of silver nanoparticles using Ganoderma neo-japonicum Imazeki: a potential cytotoxic agent against breast cancer cells, *Int. J. Nano.*, 8, 4399-4413. <https://doi.org/10.2147/IJN.S51881>
- Han, Q., Gao, L., Wang, Y., Wang, Z., He, L., Liu, B., Hu, J., Xu, B., Chen, H., 2026, Precision conversion of colorectal cancer lung metastases: A personalized quadruplet regimen integrating photodynamic therapy with targeted, immunotherapy, and chemotherapy, *Photodiagnosis. Photodyn. Ther.* 58(2026) 105362. 1-5. <https://doi.org/10.1016/j.pdpdt.2026.105362>
- He, H., Li, J., Jiang, P., Tian, S., Wang, H., Fan, R., Liu, J., Yang, Y., Liu, Z., Wang, J., 2021, The basis and advances in clinical application of boron neutron capture therapy, *Radiat. Oncol.*, 16(216), 1-8. <https://doi.org/10.1186/s13014-021-01939-7>
- Hou, J., Jeon, B., Yun, Y., Cui, C., Kim, S., 2019, Ginsenoside Rh2 ameliorates doxorubicin-induced senescence bystander effect in breast carcinoma cell MDA-MB-231 and normal epithelial cell MCF-10A. *Int. J. Mol. Sci.*, 20,(5) 1244. <https://doi.org/10.3390/ijms20051244>
- Hu, Q., Hu, S., Li, S., Liu, S., Liang, Y., Cao, X., Luo, Y., Xu, W., Wang, H., Wan, J., Feng, W., Niu, L., 2022, Boronate affinity-based electrochemical aptasensor for point-of-care glycoprotein detection, *Anal. Chem.*, 94, 10206-10212, <https://doi.org/10.1021/acs.analchem.2c01699>
- Isert, L., Mehta, A., Loiudice, G., Oliva, A., Roidl, A., Merkel, O.M., 2023, An in vitro approach to model EMT in breast cancer, *Mol.Sci.*, 24, 7757, 1-21. <https://doi.org/10.3390/ijms24097757>
- Jamil, S.N.H., Ali, A.H., Feroz, S.R., Lam, S.D., Agustar, H.K., Razak, M.A., Latip, J., 2023, Curcumin and its derivatives as potential antimalarial and anti-inflammatory agents: a review on structure-activity relationship and

- mechanism of action, *Pharmaceuticals*, 16,4, 609, https://doi.org/10.3390/ph16040609?urlappend=%3Futm_source%3Dresearchgate.net%26utm_medium%3Darticle
- Jiang, M., Zhang, K., Zhang, Z., Zeng, X., Huang, Z., Qin, P., Xie, Z., Cai, X., Ashrafzadeh, M., Tian, Y., Wei, R., 2025, PI3K/AKT/mTOR axis in cancer: from pathogenesis to treatment, *Med. Comm.*, 6:e70295, 1-51. <https://doi.org/10.1002/mco2.70295>
- Khayami, R., Hashemi, S.R., Amin, K.M., Role of aldo-keto reductase family 1 member B1 (AKRB1) in the cancer process and its therapeutic potential. *J. Cell. Mol. Med.* <https://doi.org/10.1111/jcmm.15581>
- Kitazumi, I., Tsukahara, M., 2011, Regulation of DNA fragmentation: the role of caspases and phosphorylation, *FEBS. J.*, 278, 427-441. <https://doi.org/10.1111%2Fj.1742-4658.2010.07975.x>
- Kochel, T.J., Golobeva, O.G., Fulton, A.M., 2016, Upregulation of cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) pathway member multiple drug resistance-associated protein 4 (MRP4) and downregulation of prostaglandin transporter (PGT) and 15-prostaglandin dehydrogenase (15-PGDH) in triple-negative breast cancer, *Breast Cancer (Auckl)*, 10:61-70. <https://doi.org/10.4137/bcocr.s38529>
- Kumar, H., Gupta, N.V., Jain, R., Madhunapantula, S.V., Babu, C.S., Kesharwani, S.S., Dey, S., Jain, V., 2023, A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer, *J. Adv. Res.*, 54: 271-292. <https://doi.org/10.1016/j.jare.2023.02.005>
- Laksmiani, N.P.L., Utomo, R.Y., Jenie, R.I., Hermawan, A., Nurrochmad, A., Meiyanto, E., Kirihata, M., Susidarti, R.A., 2025, *J. Pharm. Pharma. Res.*, 13(s1), S166-S189. https://doi.org/10.56499/jppres24.2267_13.s1.166
- Laksmiani, N.P.L., Utomo, R.Y., Jenie, R.I., Suenaga, Y., Kirihata, M., Meiyanto, E., Susidarti, R.A., 2026, CCB-4 and its sugar complexes induce mitotic catastrophe and p-53-independent apoptosis through caspase-2 elevation and suppression of c-Myc in T47D cells., *J. Adv. Pharm. Tech. Res.*, 17,2, 100-107., https://doi.org/10.4103/JAPTR.JAPTR_311_25
- Lee, H., Kim, M., Jeon, B., 2025, Boron-containing anticancer agents: a target-centric review of structure-activity relationship and clinical pipeline, *Archiv. Of. Pharm. Res.*, 48: 1253-1298. <https://doi.org/10.1007/s12272-025-01582-w>
- Lehman, B.D., Bauer, J.A., Chen, X.C., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., Pietenpol, J.A., 2011, identification of human triple negative breast cancer subtypes and preclinical models for selection of targeted therapies, *J. Clin. Invest.*, 121(7), 2750-2767. <https://doi.org/10.1172/jci45014>

- Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., Wang, L., 2025, Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. *Mol. Bio.*, 6, 111, 1-34. <https://doi.org/10.1186/s43556-025-00352-w>
- Li, L., Fu, J., Liu, W., Hayashi, T., Nie, Y., Mizuno, K., Hattori, S., Fujisaki, H., Onodera, S., Ikejima, T., 2020, Silibinin inhibits migration and invasion of breast cancer MDA-MB 231 cells through induction of mitochondrial fusion, *Mol. Cell. Bio.*, 463:189-201. <https://doi.org/10.1007/s11010-019-03640-6>
- Lin, Y., Lubman, D.M., 2022, The role of N-glycosylation in cancer, *Acta. Pharm. Sin. B.*, 14(3), 1098-1110. <https://doi.org/10.1016/j.apsb.2023.10.014>
- Liu, B., Yang, X., Wang, H., Liu, P., Feng, Q., Xu, C., Song, Z., 2025, Identification of hub genes for the diagnosis and prognosis in triple negative breast cancer using transcriptome and differential methylation integration analysis, *J. of Can.*, 16(6), 2026-2040. doi: 10.7150/jca.104472
- Lopes, A.A., Coppede, S., Amatto, P.P.G., Aragon, D.C., Franca, S.C., Carmona, F., Pereira, A.M.S., 2025, Cytotoxic effect of different *Uncaria tomentosa* (cat's claw) extracts, fractions on normal and cancer cells : a systematic review, *Front. Pharm.*, 16, 1-12,. <https://doi.org/10.3389/fphar.2025.1584840>
- Majtnerova, P., Rousar, T., 2018, An overview of apoptosis assays detecting DNA fragmentation, *Mol. Bio. Rep.*, 1-10. <https://doi.org/10.1007/s11033-018-4258-9>
- Maristany, F., Filosto, S., Catchpole, S., Marlow, R., Quist, J., 2016, PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer, *Nat. Med.*, 22, 11, 1303-1318.
- Matassov, D., Kagan, T., Leblanc, J., Sikorska, M., Zakeri, Z., 2004, Measurement of apoptosis by DNA fragmentation, *Methods in Molecular Biology*, 282, 1-17,
- Meiyanto, E., Putri, H., Larasati, Y.A., Utomo, R.Y., Jenie, R.I., Ikawati, M., Lestari, B., Kato, N.Y., Nakamae, I., Kawaichi, M., Kato, J., 2019, Anti-proliferative and anti-metastatic potential of curcumin analogue, pentagamavunon-1 (PGV-1, toward highly metastatic breast cancer cells in correlation with ROS Generation, *Adv. Pharm. Bull.*, 9(3), 445-452. <https://doi.org/10.15171/apb.2019.053>
- Meiyanto, E., Husnaa, U., Kastian, R.K., Putri, H., Larasati, Y.A., Khumaira, Pamungkas, D.D.P., Jenie, R.I., Kawaichi, M., Lestari, B., Yokoyama T., Kato, J., The target differences of anti-tumorigenesis potential of curcumin and its analogues against HER-2 positive and triple-negative breast cancer cells., *Adv. Pharm. Bull.*, 11,1, 118-196. <https://apb.tbzmed.ac.ir/>
- Meiyanto, E., Susidarti, RA, Jenie, R.I., Utomo, R.Y., Novitasari, D., Wulandari, F., Kirihata, M., 2020, Synthesis of new boron containing compound (CCB-

- 2) based on curcumin structure and its cytotoxic effect against cancer cells, *J. Appl. Pharm. Sci.*, 10(02), 60-66.
<https://dx.doi.org/10.7324/JAPS.2020.102010>
- Migliaccio, G., Ferraro, R., Wang, Z., Cristini, V., Dogra, P., Caserta, S., 2023, Exploring cell migration mechanisms in cancer: from wound healing assay to cellular automata models, *Cancers*, 15, 5284, 1-14.
<https://doi.org/10.3390/cancers15215284>
- Mohammed, F., Doubell, F., Taha, S., Cassidy, S., Fredericks, S., 2020, Effects of curcumin complexes on MDA-MB-231 breast cancer cell proliferation, *Int. J. Onc.*, 57, 445-455. 10.3892/ijo.2020.5065
- Mohamed, S.A., El-Shistawy, R., Al-Bar, O.A.M., Al-Najada, A.R., 2017, Chemical modification of curcumin: solubility and antioxidant capacity, *Int. J. Food. Pro.* 20(3), 718-724. <https://doi.org/10.1080/10942912.2016.1177545>
- Mohanty M., Mohanty, P.S., 2023, Molecular docking in organic, inorganic, and hybrid systems: a tutorial review, *Monatsh Chem*, 6, 1-25,
<https://doi.org/10.1007/s00706-023-03076-1>
- Mondal R., Noushija M., K., Banu S., P., Pandurangan N., Shanmuragaju S. 2014. A mini-review on ru(II)-curcumin metal complexes based anticancer agents. *In. Chi. Acta.*, 569: 1-15. <https://doi.org/10.1016/j.ica.2024.122156>
- Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., Olson, A.J., 1998, Automated docking using a Lamarckian genetic algorithm and an empirical binding energy function, *Com. Chem.*, 19(14), 1639-1662.
- Nomura, D.K., Lombardi, D.P., Chang., J.W., et.al., 2011, Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer, *Chem. Biol.*, 18, 7, 846-856,
<https://doi.org/10.1016/j.chembiol.2011.05.009>
- Orrantia, E., Anchondo, P., Acuna, L. E., Valles, F. O. G., Adriana, R. V., 2022, Subtypes of Breast Cancer, Brisbane (AU): Exon Publications.
<https://doi.org/10.36255/exon-publications-breast-cancer>
- Owida, H. A., Mohammad, S.I., Vasudevan, A., Bishoyi, A. K., RenukaJyothi, S. Panigrahi, R., Abosaoda, M.K., Garg, G., Pargaian, A., 2026, Kinesin superfamily proteins in cancer: unveiling their role in chemotherapy, *Int. Imm.*, 166(2025)115621, 1-18. <https://doi.org/10.1016/j.intimp.2025.115621>
- Peng, S., Fu, Y., 2023, FYN: emerging biological roles and potential therapeutic targets in cancer, *J. Transl. Med.*, 21, 84, 1-17.
<https://doi.org/10.1186/s12967-023-03930-0>
- Prasad, S., DuBourdieu, D., Srivastava, A., Kumar, P., Lall, R., 2021, Metal-curcumin complexes in therapeutics: an approach to enhance pharmacological effects of curcumin, *Mol. Sci.*, 22, 13, 7094.
<https://doi.org/10.3390/ijms22137094>

- Priyadarsini K.I., 2013, Chemical and structural features influencing the biological activity of curcumin, *Curr. Pharm. Des.*, 19 (11), 2093-2100. <http://dx.doi.org/10.2174/1381612811319110010>
- Que, W., Chen, M., Yang, L., Zhang, B., Zhao, Z., Liu, M., Cheng, Y., Qiu, H., 2021. A network pharmacology-based investigation on the bioactive ingredients and molecular mechanisms of *Gelsemium elegans* Benth, *BMC. Com. Med. Ther.*, 21:99. 1-18. <https://doi.org/10.1186/s12906-021-03273-7>
- Saadat, Y.R., Saeidi, N., Vahed, S.Z. Barzegari, A., Barar, J., 2015, An update to DNA ladder assay for apoptosis detection, *Bioimpacts*, 5(1), 25-28. <http://bi.tbzmed.ac.ir/>
- Sandholm, J., Selander, K.S., 2014, Toll-like receptor 9 in breast cancer, *Front. Immunol.*, 5, 330, 1-6. <http://www.frontiersin.org/Immunology/editorialboard>
- Sayequa, D. 2021. Mechanisms adopted by cancer cells to escape apoptosis: a review. *Biocell*, 45(4): 863-884. 10.32604/BIOCELL.2021.013993
- Singel, S.M., Batten, K., Cornelius, C., Jia, G., Fasciani, G., Barron, S., Wright E.W., Shay, J.W., 2014, Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion of nuclear factor-kappaB and c-jun N-terminal kinase pathways, *Breast Cancer Research*, 16, R28, 1-14. <http://breast-cancer-research.com/content/16/2/R28>
- Silva, M.P., Saraiva, L., Pinto, M., Sousa, M.E., 2020, Boronic acid and their derivatives in medical chemistry: synthesis and biological applications, *Molecules*, 25, 4323, 1-40, <http://dx.doi.org/10.3390/molecules25184323>
- Soofi, A., Taghizadeh, M., Tabatabaei, S.M., Tavirani, M.R., Shakib, H., Namaki, S., Alighiarloo, N.S., 2020, Centrality analysis of protein-protein interaction networks and molecular docking prioritize drug-targets in type 1 diabetes, *Iran. J. Pharm. Res.*, 19(4), 121-134.
- Song, S., Gao, P., Sun, L., Kang, D., Kongsted, J., Poongavanam, V., Zhan, P., Liu, X., 2021, Recent developments in the medicinal chemistry of single boron atom-containing compounds, *Acta. Pharm. Sin. B.*, 11(10), 3035-3059. <https://doi.org/10.1016/j.apsb.2021.01.010>
- Stojchevski, r., Sutanto, E., A., Sutantu, R., Petrushev, N., H., Mladenov, M., Singh, S., R., Sinha, J., K., Ghosh, S., Yarlagadda, B., Singh, K., K., Verma, P., Sengupta, S., Bhaskar, R., Avtanski, D. 2025. Translational advances in oncogene and tumor-suppressor gene research. *Cancers*, 17(1008): 1-47. <https://doi.org/10.3390/cancers17061008>
- Su, S., Luo, J., Wang, F., Li, S., Gao, Y., Yan, L., 2025, The potential mechanism of antitumor lung cancer by Chinese medicine Huang Qin: based on bioinformatics molecular, network pharmacology and imaging histology

analysis, *Rad. Res. App. Sci.*, 18. 1-14.
<https://doi.org/10.1016/j.jrras.2025.101381>

Suhadi A, Rizarullah R, Feriyani F. 2019. Simulasi docking senyawa aktif daun binahong sebagai inhibitor enzyme aldose reductase. *Sel Jurnal Penelitian Kesehatan*. 6(2):55-65.

Survei Kesehatan Indonesia (SKI) 2023 dalam Angka, “Kementerian Kesehatan Republik Indonesia”, Badan Kebijakan Pembangunan Kesehatan, 2024. Diakses 23 Maret 2026. [Daring]. Tersedia pada:
<https://layanandata.kemkes.go.id/katalog-data/ski/ketersediaan-data/ski-2023>

Suselo, Irmawan S., M, Patimah S. 2023. Life experience of women with breast cancer undergoing chemotherapy at Jayapura General Hospital, Indonesia. *Sriwijaya, J. Sur.*, 9(2): 563-567. <https://doi.org/10.37275/sjs.v6i2.91>

Susidarti, R.A., Utomo, R.Y., Qodria, L., Ramadani, R.D., Ohta, Y., Hattori, Y., Kiriata, M., Meiyanto, E., 2019, Preparation of pentagamaboron-0 and its fructose and sorbitol complexes as boron carrier for boron neutron capture therapy (BNCT) application, *Res. Pharm. Sci.*, 14(4), 286-292.
<https://doi.org/10.4103/1735-5362.263552>

Tacar, O., Sriarmornsak, P., Dass, C.R., 2013, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems, *J. Pharm. Pharm.*, 65, 157-170.

Tatar, C., Avei, C.B., Acikgoz, E., Oktem, G., 2023, Doxorubicin-induced senescence promotes resistance to cell death by modulating genes associated with apoptotic and necrotic pathways in prostate cancer DU145 CD133⁺/CD44⁺ cells, *Biochem. Biophys. Commun.*, 680: 85-93.
<https://doi.org/10.1016/j.bbrc.2023.09.032>

Tripathi, A., Suri, K., K, Sriram, Murugan, N.A., 2025, Assessing the accuracy of binding pose prediction for kinase proteins and 7-azaindole inhibitors: a study with AutoDock4, Vina, DOCK6, and GNINA 1.0, *RSC. Adv.*, 15, 47051-47065. <https://doi.org/10.1039/D5RA05526A>

Tsang, J.Y.S., Le, M.A, Ni, Y.B., et.al., 2018, Amyloid precursor protein was associated with aggressive behavior in non-luminal breast cancer, *The Oncologist*, 23, 11, 1273-1281

Utomo, R.Y., Wulandari, F., Novitasari, D., Lestari, B., Susidarti, R.A., Jenie, R.I., Kato, J., Sardjiman, S., Meiyanto, E., 2022, Preparation and cytotoxic evaluation of PGV-1 derivative, CCA-1.1, as a new curcumin analog with improved-physicochemical and pharmacological properties, *Adv. Pharm. Bull.*, 12(3), 603-612. <https://doi.org/10.34172/apb.2022.063>

- Urosevic M., Nikolic, L., Gajic, I., Nikolic, V., Dinic, A., Miljkovic, V., 2022, Curcumin: biological activities and modern pharmaceutical forms, *Antibiotics.*, 11, 135, 1-27. <https://doi.org/10.3390/antibiotics11020135>
- Vale, N., Silva, S., Duarte, D., Crista, D.M.A., Pinto, S., Esteves, S., 2021, Normal breast epithelial MCF-10A cells to evaluate the safety of carbon dots. *RSC medicinal Chemistry*, 12(9), 245-253. <https://doi.org/10.1039/d0md00317d>
- Wadhwa, B., Paddar, M., Khan, S., Mir, S., Clarke, P.A., Grabowks, A.M., Vijay, D.G., Malik, F., 2020, AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity, *Oncotarget*, 11, 45, 4178-4194. [10.18632/oncotarget.27746](https://doi.org/10.18632/oncotarget.27746)
- Walker, P.R., Sikorska, M., 1994, Endonuclease activities, chromatin structure, and DNA degradation in apoptosis, *Biochemistry and Cell Biology*, 72(11- 12), 615-623. <https://doi.org/10.1139/o94-081>
- Welsh, J., 2013, Animal Models for Studying Prevention and Treatment of Breast Cancer, *Animal Models for Study of Human Disease*, 997-1018, Elsevier, <http://dx.doi.org/10.1016/B978-0-12-415894-8.00040-3>
- Widiandani, T., Tandian, T., Zufar, B.D., Suryadi, A., Purwanto, B.T., Hardjono, S., Siswandono, 2022, In vitro study of pinostrobin propionate and pinostrobin butyrate: cytotoxic activity against breast cancer cell T47D and its selectivity index, 14, S1, 2516. <https://doi.org/10.4081/jphia.2023.2516>
- Wilkinson, A. N., Ellison, L.F., McGee, S.F., Billete, J.M., Seely, J. M., 2024, The landscape of breast cancer molecular and histologic subtypes in Canada, *Cur. Onc.*, 31, 5544-5556. <https://doi.org/10.3390/curroncol31090411>
- Xiong, N., Wu, H., Yu, Z., 2024, Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies, *Front. In. Onc.*, 14:1405491, 1-12. <https://doi.org/10.3389/fonc.2024.1405491>
- Xu, M., Shan, D., Zhang, R., Li, J., Guo, L., Chen, X., Qu, J., 2025, Differentiation of breast cancer subtypes and correlation with biological status using functional magnetic resonance imaging: comparison with amide proton transfer-weighted imaging and diffusion-weighted imaging, *Quant. Imag. Med. Surg.*, 15(7), 6102-6117. <https://dx.doi.org/10.21037/qims-24-2174>
- Yao, Z. J., Dong, J., Che, Y. J., Zhu, M. F., Wen, M., Wang, N., N., Wang, S., Lu, A.P., Cao, D.S., 2016, TargetNet: a web service for predicting potential drug-target interaction profiling via multi-target SAR models, *Com. Aid. Mol. Des.*, 30, 413-424. <http://dx.doi.org/10.1007/s10822-016-9915-2>
- Yin, L., Duan, J., Bian, X., Yu, S., 2020, Triple-negative breast cancer molecular subtyping and treatment progress, *Breast. Can. Res.*, 22(61); 1-13. <https://doi.org/10.1186/s13058-020-01296-5>

- Zattarin, E., Taglialatela, I., Lobefaro, R., Leporati, R., Fuca, G., Ligorio, F., Sposetti, C., Provenzano, L., Azzolini, J., Vingiani, A., Ferraris, C., Martelli, G., Manoukian, S., Pruneri, G., Braud, F., Vernieri, C., 2023, Breast cancer arising in subjects with germline BRCA1 or BRCA2 mutations: different biological and clinical entities with potentially diverse therapeutic opportunities, *Cri. Rev. On. Hem.*, 190, 1-13. <https://doi.org/10.1016/j.critrevonc.2023.104109>
- Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., Wu, C., 2024, Tumor initiation and early tumorigenesis: molecular mechanisms and interventional target, *Sig. Trans. Tar. Ther.*, 9 (149), 1-36. <https://doi.org/10.1038/s41392-024-01848-7>
- Zhang, H., Jiang, R., Zhu, J., Sun, K., Huang, Y., Zhou, H., Zheng, Y., Wang, X., 2024, PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer, *Breast Cancer*, 31:539-551. <https://doi.org/10.1007/s12282-024-01567-5>
- Zhou, Z., Zhong, H., Wang, H., Wang, S., Kridis, W.B., Wang, R., Sen, K., Wang, Z., Huang, R., 2025, Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications, *Discover Oncology*, 16:1973, 1-34. <https://doi.org/10.1007/s12672-025-03797-1>
- Zhu, X., Zhou, W., 2015, The emerging regulation of VEGFR-2 in triple negative breast cancer, *Front Endocrinol (Lausanne)*, 6, 159,
- Zia, B., Meeran, N., Sharma, C., Mirza, S., Ojha, S.K., 2025, Therapeutic potential and pharmacological mechanisms of cannabinoids in alleviating chemotherapy-induced organ toxicity and adverse effects, *Eur. J. Pharmacol*, 978: 178646, 1-21. <https://doi.org/10.1016/j.ejphar.2026.178646>
- Zoi, V., Galani, V., Lianos, G.D., Voulgaris, S., Kyritsis, A.P., Alexiou, G.A., 2021, The role of curcumin in cancer treatment, *Biomedicines*, 9, 1086, 1-19. <https://doi.org/10.3390/biomedicines9091086>
- Zoi, V., Kyritsis, A.P., Galani, V., Lazari, D., Sioka, C., Voulgaris, S., Alexiou, G.A., 2024, The role of curcumin in cancer: a focus on the PI3K/Akt pathway, *Cancers.*, 16, 1554, 1-22. <https://doi.org/10.3390/cancers16081554>